We are excited to announce the appointment of Yonghong Zhu, M.D., Ph.D., as CMO, overseeing all clinical development activities for the company’s clinical stage assets. Welcome to the team, Dr. Zhu!
Read the full press release here: bwnews.pr/43FokM4
62
We are excited to announce the U.S. FDA clearance of IND application for a Phase Ib/II trial of our EMB-01 #bispecific program in combination with @AstraZeneca’s #Tagrisso for non-small cell lung cancer. Read more: https://xitter.gq/t.co/X7AlL9Rrqf
1
Our CBO/COO Stephan Lensky will be attending #BIO2022 on June 13-16. Reach out to schedule a meeting with our team to learn more about EpimAb’s #bispecific pipeline and corporate updates. https://xitter.gq/t.co/nUa76AP5KB
Our team will be presenting at @PEGSBoston on May 4 from 5:30-6pm EST. Join us to learn more about our #bispecific antibody programs. https://xitter.gq/t.co/XZ1Fr4AQN6 #PEGS22 #innovation #biotech
Our CFO David Gu is presenting at the Oppenheimer Annual Healthcare Conference on March 16th at 8am ET. He will be discussing EpimAb’s proprietary #bispecific antibody technology, corporate strategy, and updates on our clinical programs. https://xitter.gq/t.co/9lZZtfCV7v
1
As we approach #JPM22, we look forward to exciting industry conversations. Interested in setting up a meeting with our team? We’d love to discuss our bispecific antibody assets and platforms [email protected] #innovation #biotech #BiotechShowcase
2
Our founder and CEO Chengbin Wu is presenting at the 8th @BioCentury-BayHelix China Healthcare Summit as part of the “hot topics” track. His presentation will be available on demand on Nov 16. Tune in to learn about our #bispecific antibody programs. https://xitter.gq/t.co/6YdjrN3WPb
Our COO/CBO Stephan Lensky will be participating in the partnering system at @EBDgroup’s #BIOEUROPE Digital next week. Reach out to schedule a meeting. https://xitter.gq/t.co/JErF6Uj3MR
1
2
We’re excited to welcome Dr. Andrew Zhu to our SAB. He has an impressive track record of clinical expertise and innovation and as a physician-scientist, will substantially contribute to our strategy as we advance 3 programs through clinical development: https://xitter.gq/t.co/0YtEfdpmsD
1
We are excited to continue the momentum of our pipeline advancement & further validate the power of our FIT-Ig platform with the dosing of the first patients in Phase 1/2 trials for EMB-02 and EMB-06 as well as the IND clearance for EMB-02 in China. https://xitter.gq/t.co/GAvlgRcjuR
1
2
EMB-02 is a #bispecific antibody targeting #PD1 and #LAG3. This target combination could be effective in treating cancers resistant to current therapies. In preclinical studies EMB-02 showed significant improvement in models resistant to PD-1 therapies. https://xitter.gq/t.co/XEVlkYx2J4
1
2
EMB-06 is a #bispecific antibody targeting #BCMA and #CD3 in patients with recurrent and refractory multiple myeloma. The clinical trial is being conducted in Australia with plans to expand to additional countries. https://xitter.gq/t.co/XEVlkYx2J4
1
We look forward to attending #BIODigital June 10-11 & 14-18. Reach out to schedule a meeting with our team on @bio1x1 to learn about EpimAb’s latest corporate development and plans for advancing #bispecifics innovation. https://xitter.gq/t.co/ekcbjaRFYL
An informative article on the evolving #bispecifics landscape and how bispecifics’ effects on receptor internalization & co-degradation open up new opportunities for #ADCs development. Check out the full story including our CEO Chengbin Wu’s insights here: https://xitter.gq/t.co/42TMNCKIPf
Fresh off a first FDA approval, bispecific antibodies that target two tumor antigens instead of immune regulators are showing momentum at #ASCO21, and stand to open new doors for ADCs. buff.ly/2TbkJpZ
1
Our Founder and CEO Chengbin Wu will be delivering a corporate presentation at the 2021 Jefferies Virtual Healthcare Conference on June 3. https://xitter.gq/t.co/mcv15MObZ3
1
We’re proud to announce that Jerry Su has been promoted to CTO. Dr. Su joined EpimAb in 2019 and has been instrumental in EpimAb’s growth and CMC development. We look forward to his continued contribution and leadership. https://xitter.gq/t.co/atffVsgwyd #ChinaBiotech #bispecifics
2
If you are attending #ChinaBio next week, check out our Founder and CEO Chengbin Wu’s on-demand presentation discussing EpimAb’s bispecifics development strategy and clinical progress. Reach out to schedule a meeting! https://xitter.gq/t.co/DP7jJbXaN9 #ChinaBioPartnering
1
We are proud to announce a $120M Series C financing, which will support our pipeline as we advance 3 #bispecific programs through the clinic. We thank our team & investors for their support & welcome new Board members from CMBI and Mire Asset Global bwnews.pr/3vQFm9K
EpimAb COO/CBO Stephan Lensky will be virtually attending the China Healthcare Investment Conference (CHIC) put on in partnership with @endpts March 23-25. Reach out to set a meeting and learn more about EpimAb’s #bispecific programs and recent progress. https://xitter.gq/t.co/OTedczNpP6
1
We're excited to kick off this year with a presentation by our COO/CBO Stephan Lensky at #JPM2021 on Jan 11. Check it out and reach out to set up a meeting to learn more about EpimAb’s growing pipeline of #bispecifics and 2021 plans. #JPM21 #ChinaBiotech https://xitter.gq/t.co/QIcdP3zhqq
2

















